Context Therapeutics Inc. (6K9.F)
Frankfurt · EUR · Healthcare · Biotechnology
€0.15 (-21.87%) as of
Key statistics
- Market cap
- 13.78M
- EPS (TTM)
- -0.5300
- Dividend yield
- 0.00%
- 52-week range
- 0.1470 – 3.1200
- Beta
- 1.72
- Profit margin
- 0.00%
- Volume
- 3.00k
About Context Therapeutics Inc.
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company's product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. It has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Philadelphia, PA, United States
- Employees
- 15
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.